These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34575409)

  • 41. Unpredictable In Vitro Killing Activity of Amphotericin B against Four
    Papp Z; Borman AM; Forgács L; Kovács R; Tóth Z; Chun-Ju C; Kardos G; Juhász B; Szilvássy J; Majoros L
    Pathogens; 2021 Aug; 10(8):. PubMed ID: 34451454
    [No Abstract]   [Full Text] [Related]  

  • 42.
    Arendrup MC; Jørgensen KM; Hare RK; Chowdhary A
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antifungal therapies in murine infections by Candida kefyr.
    Sanchis M; Martin-Vicente A; Capilla J; Guarro J
    Mycoses; 2016 Apr; 59(4):253-258. PubMed ID: 26857550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
    Nooney L; Matthews RC; Burnie JP
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification and Antifungal Drug Susceptibility Pattern of
    Deshkar S; Patil N; Amberkar S; Lad A; Siddiqui F; Sharan S
    J Glob Infect Dis; 2022; 14(4):131-135. PubMed ID: 36636301
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.
    Hall D; Bonifas R; Stapert L; Thwaites M; Shinabarger DL; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Nov; 89(3):205-211. PubMed ID: 28826987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Farnesol increases the activity of echinocandins against Candida auris biofilms.
    Nagy F; Tóth Z; Daróczi L; Székely A; Borman AM; Majoros L; Kovács R
    Med Mycol; 2020 Apr; 58(3):404-407. PubMed ID: 31127836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of efficacy of echinocandins against high metabolic activity biofilms of Candida parapsilosis clinical isolates.
    Thomaz DY; Melhem MSC; de Almeida Júnior JN; Benard G; Del Negro GMB
    Braz J Microbiol; 2020 Sep; 51(3):1129-1133. PubMed ID: 31898245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
    Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Bidaud AL; Botterel F; Chowdhary A; Dannaoui E
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31591129
    [No Abstract]   [Full Text] [Related]  

  • 51. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Hacioglu M; Birteksoz Tan AS; Dosler S; Inan N; Otuk G
    PeerJ; 2018; 6():e5263. PubMed ID: 30065873
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Hager CL; Larkin EL; Long L; Zohra Abidi F; Shaw KJ; Ghannoum MA
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311065
    [No Abstract]   [Full Text] [Related]  

  • 54. In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against
    Caballero U; Eraso E; Pemán J; Quindós G; Vozmediano V; Schmidt S; Jauregizar N
    Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834182
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Vatanshenassan M; Boekhout T; Meis JF; Berman J; Chowdhary A; Ben-Ami R; Sparbier K; Kostrzewa M
    Front Cell Infect Microbiol; 2019; 9():20. PubMed ID: 30834236
    [No Abstract]   [Full Text] [Related]  

  • 56. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial Results of the International Efforts in Screening New Agents against
    Poester VR; Munhoz LS; Benelli JL; Melo AM; Al-Hatmi AMS; Larwood DJ; Martinez M; Stevens DA; Xavier MO
    J Fungi (Basel); 2022 Jul; 8(8):. PubMed ID: 35893139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against
    Tóth Z; Forgács L; Kardos T; Kovács R; Locke JB; Kardos G; Nagy F; Borman AM; Adnan A; Majoros L
    J Fungi (Basel); 2020 Aug; 6(3):. PubMed ID: 32824464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
    Ernst EJ; Klepser ME; Pfaller MA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.